Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CABA Cabaletta Bio Inc
- Stocks
- Healthcare
- NASDAQ: CABA
Price (delayed)
$1.15
Market cap
$58.35M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.34
Enterprise value
-$90.01M
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative,
Highlights
CABA's net income has dropped by 71% year-on-year and by 11% since the previous quarter
Cabaletta Bio's quick ratio has shrunk by 60% YoY and by 24% QoQ
Key stats
What are the main financial stats of CABA
Market
Valuations
Earnings
Shares outstanding
50.74M
Market cap
$58.35M
Enterprise value
-$90.01M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.37
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$125.14M
Net income
-$115.86M
EBIT
-$115.12M
EBITDA
-$110.57M
Free cash flow
-$90.43M
Per share
Balance sheet
Liquidity
EPS
-$2.34
EPS diluted
-$2.34
Free cash flow per share
-$1.85
Book value per share
$3.12
Revenue per share
$0
TBVPS
$3.79
Total assets
$185.05M
Total liabilities
$32.71M
Debt
$15.6M
Equity
$152.34M
Working capital
$139.59M
Debt to equity
0.1
Current ratio
6.15
Quick ratio
6.05
Net debt/EBITDA
1.34
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-54.7%
Return on equity
-62%
Return on invested capital
-385.6%
Return on capital employed
-72.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CABA stock price
How has the Cabaletta Bio stock price performed over time
Intraday
-10.16%
1 week
-10.16%
1 month
3.6%
1 year
-91.06%
YTD
-49.34%
QTD
-16.97%
Financial performance
How have Cabaletta Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$125.14M
Net income
-$115.86M
Gross margin
N/A
Net margin
N/A
CABA's net income has dropped by 71% year-on-year and by 11% since the previous quarter
The operating income has plunged by 68% YoY and by 9% from the previous quarter
Price vs fundamentals
How does CABA's price correlate with its fundamentals
Growth
What is Cabaletta Bio's growth rate over time
Valuation
What is Cabaletta Bio stock price valuation
P/E
N/A
P/B
0.37
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CABA's EPS is down by 42% YoY and by 8% QoQ
CABA's price to book (P/B) is 82% lower than its 5-year quarterly average of 2.1 and 81% lower than its last 4 quarters average of 1.9
The equity has contracted by 36% YoY and by 13% from the previous quarter
Efficiency
How efficient is Cabaletta Bio business performance
The ROIC has plunged by 125% YoY and by 47% from the previous quarter
Cabaletta Bio's ROE has plunged by 52% YoY and by 24% from the previous quarter
Cabaletta Bio's return on assets has decreased by 44% YoY and by 20% QoQ
Dividends
What is CABA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CABA.
Financial health
How did Cabaletta Bio financials performed over time
Cabaletta Bio's total liabilities has soared by 87% YoY and by 8% from the previous quarter
Cabaletta Bio's quick ratio has shrunk by 60% YoY and by 24% QoQ
CABA's debt is 90% smaller than its equity
The equity has contracted by 36% YoY and by 13% from the previous quarter
Cabaletta Bio's debt to equity has increased by 11% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.